Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CBLB | Q13191 | 7/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051873 | 1.00 | NPY1R (0.54) | NPY1RDRD3HTR2AHTR1ACHRNA7 | |
| SCHEMBL7051385 | 0.88 | NPY1R (0.55) | NPY1REGFRMAPT | |
| SCHEMBL7051383 | 0.88 | NPY1R (0.55) | NPY1REGFRMAPT | |
| SCHEMBL7058673 | 0.87 | NPY1R (0.51) | NPY1RHTR1ACBLBMAPT | |
| SCHEMBL7058676 | 0.87 | NPY1R (0.51) | NPY1RHTR1ACBLBMAPT | |
| SCHEMBL7057389 | 0.86 | MAPT (0.50) | NPY1RDRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7055493 | 0.86 | NPY1R (0.52) | NPY1RDRD3HTR2AHTR1ADRD2 | |
| SCHEMBL7057391 | 0.86 | MAPT (0.50) | NPY1RDRD3HTR2AHTR1AHTR2C | |
| SCHEMBL7055492 | 0.86 | NPY1R (0.52) | NPY1RDRD3HTR2AHTR1ADRD2 | |
| SCHEMBL7055133 | 0.85 | NPY1R (0.55) | NPY1RDRD3HTR2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316617-B1 | FOR TREATING PHYSIOLOGICAL DISORDERS ASSOCIATED WITH AN EXCESS OF NEUROPEPTIDE Y, SUCH AS FEEDING DISORDERS AND CERTAIN CARDIOVASCULAR DISEASES, MEDICAL DIAGNOSIS | NEUROGEN CORPORATION | 2001-11-13 | — | — | US | claimed |
| EP-0918761-B1 | CERTAIN AMIDO- AND AMINO-SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTITE Y1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6316617-B1 | FOR TREATING PHYSIOLOGICAL DISORDERS ASSOCIATED WITH AN EXCESS OF NEUROPEPTIDE Y, SUCH AS FEEDING DISORDERS AND CERTAIN CARDIOVASCULAR DISEASES, MEDICAL DIAGNOSIS | NEUROGEN CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6133265-A | Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands | NEUROGEN CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |